论文部分内容阅读
目的:对老年与非老年组多发性骨髓瘤患者的血清TRacp-5b及IL-6水平进行分析。方法:2011年3月至2015年3月本院收治50例多发性骨髓瘤患者按年龄分为老年组与非老年组(老年组26例非老年组24例),选取健康献血员血清30份作为对照组,所有对照组及患者采用酶联免疫吸附测试法进行血清血清抗酒石酸酸性磷酸酶(TRacp-5b)及白介素6(IL-6)水平水平测试。对两组患者的结果及疾病的发生、转归及预后进行分析。结果:50例患者平均血清TRacp-5b水平为5.6±0.5U/L,IL-6水平为109.62±0.5pg/ml。远高于30例对照组水平(2.8±0.5 U/L及41.25±0.5pg/ml(P<0.05)。老年组TRacp-5b及IL-6水平分别为6.8±0.5 U/L及159.45±0.5 pg/ml,非老年组TRacp-5b及IL-6水平分别为5.1±0.5U/L及91.25±0.5pg/m。两组患者的TRacp-5b水平及IL-6水平老年组患者均明显高于非老年组(P<0.05)。结论:多发性骨髓瘤患者血清TRacp-5b及IL-6水平均远高于正常健康献血员(P<0.05),老年组患者血清TRacp-5b及IL-6水平远高于非老年组患者(P<0.05),TRacp-5b及IL-6水平的检测对于疾病的早期治疗及预后分析具有较高价值。
Objective: To analyze the levels of TRacp-5b and IL-6 in patients with multiple myeloma in the elderly and non-elderly groups. Methods: From March 2011 to March 2015, 50 patients with multiple myeloma treated in our hospital were divided into the elderly group and the non-elderly group according to the age (24 elderly non-elderly group, 24 cases), 30 healthy donors serum Serum levels of TRacp-5b and IL-6 in serum were measured by enzyme linked immunosorbent assay (ELISA) in all controls and patients. The results of two groups of patients and the incidence of disease, prognosis and prognosis were analyzed. Results: The mean serum levels of TRacp-5b in 50 patients were 5.6 ± 0.5 U / L and IL-6 was 109.62 ± 0.5 pg / ml. (P <0.05). The levels of TRacp-5b and IL-6 in the elderly group were 6.8 ± 0.5 U / L and 159.45 ± 0.5 pg / ml, TRacp-5b and IL-6 in non-elderly group were 5.1 ± 0.5U / L and 91.25 ± 0.5pg / m respectively.The levels of TRacp-5b and IL-6 in the two groups were significantly higher in elderly patients (P <0.05) .Conclusion: The levels of TRacp-5b and IL-6 in patients with multiple myeloma are much higher than those in normal healthy donors (P <0.05). The levels of TRacp-5b and IL- 6 levels were much higher than those in non-elderly patients (P <0.05). Detection of TRacp-5b and IL-6 levels was of great value in the early treatment and prognosis of the disease.